UNH 13F filer interest

What happened: Hedge funds and investment banks have shown increased interest in UnitedHealth Group (UNH). On May 22, UBS analyst AJ Rice raised UNH's price target to $460, a 12.2% increase from the previous target of $410, while maintaining a 'Buy' rating. Goldman Sachs added UNH to its U.S. Conviction List on May 1, expressing confidence in the company. Meanwhile, 34 out of 59 recently reviewed 13F filings held UNH, indicating significant hedge fund interest.

Market impact: This increased interest from prominent financial institutions has driven UNH's stock price up by 10.5% since May 1, outpacing the S&P 500's 3.6% gain during the same period. The healthcare sector, particularly managed care, has seen a boost, with UNH's peers like CVS Health and Anthem also experiencing price increases.

What to watch next: UNH's Q2 earnings report on July 14 will provide insights into the company's performance and guidance. Additionally, investors should monitor any updates to UNH's price targets by UBS and Goldman Sachs, as well as changes in hedge fund ownership as reflected in future 13F filings. Lastly, keep an eye on any regulatory developments that could impact the managed care industry.